Levofloxacin Injection
NDC Package 63323-355-60
Package Information
Levofloxacin injection is levofloxacin in 5% Dextrose Injection is indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Levofloxacin in 5% Dextrose Injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). This formulation utilizes a injection delivery system. Marketed by Fresenius Kabi Usa, Llc, this product is identified by NDC 63323-355 and is authorized under FDA application ANDA200674.
Identification & Billing
- RxCUI: 1665497 - levoFLOXacin 250 MG in 50 ML Injection
- RxCUI: 1665497 - 50 ML levofloxacin 5 MG/ML Injection
- RxCUI: 1665497 - levofloxacin 250 MG per 50 ML Injection
- RxCUI: 1665507 - levoFLOXacin 500 MG in 100 ML Injection
- RxCUI: 1665507 - 100 ML levofloxacin 5 MG/ML Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 63323 - Fresenius Kabi Usa, Llc
- 63323-355 - Levofloxacin
- 63323-355-60 - 1 BAG in 1 POUCH / 150 mL in 1 BAG
- 63323-355 - Levofloxacin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (63323-355). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 63323-355-60 identifies a specific commercial package of 1 bag in 1 pouch / 150 ml in 1 bag of Levofloxacin, a human prescription drug labeled by Fresenius Kabi Usa, Llc. This product is billed per "ML" milliliter and contains an estimated amount of 150 billable units per package. This injection is formulated for intravenous use and contains levofloxacin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Fresenius Kabi Usa, Llc on June 20, 2013. The current certification is valid through December 31, 2027.
How is this Fresenius Kabi Usa, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 63323035560. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 150 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.